Ecolab Life Sciences Presentation: Future-Proof Bio-decontamination in Your Cell and Gene Therapy Process and Facility
Wednesday, May 29, 2024 07:15 PM - 07:30 PM
Exhibit Hall - Theatre B
Global Showcase Presentation
Presenter(s)
One of the biggest challenges for developers and manufacturers of cell and gene therapies (ATMPs) is to design a robust process to transfer living material into closed systems such as isolators, without introducing contamination into the grade A/ISO 5 area or damaging them from the bio-decontamination process. Consistency and quality of a bio-decontamination program for processes and cleanroom facilities depend on a pragmatic approach and understanding of the risks to patients and products. Modern approaches, combining manual and automated applications, to bio-decontamination can align to reduce risks. We will describe how automated bio-decontamination systems can be integrated into current and future cell and gene therapy processes and facilities, to meet patient and compliance needs.
- Donald Singer, Senior Microbiology Technical Consultant, North America, Ecolab Life Sciences, USA
- David Root, Manager, Service Support, Ecolab Life Sciences, USA
One of the biggest challenges for developers and manufacturers of cell and gene therapies (ATMPs) is to design a robust process to transfer living material into closed systems such as isolators, without introducing contamination into the grade A/ISO 5 area or damaging them from the bio-decontamination process. Consistency and quality of a bio-decontamination program for processes and cleanroom facilities depend on a pragmatic approach and understanding of the risks to patients and products. Modern approaches, combining manual and automated applications, to bio-decontamination can align to reduce risks. We will describe how automated bio-decontamination systems can be integrated into current and future cell and gene therapy processes and facilities, to meet patient and compliance needs.
SPONSORED BY:
